Dual-release levodopa formulation IPX203 has received expert-consensus endorsement for use in European patients with Parkinson’s motor fluctuations, targeting improved timing of dopamine delivery. Separately, new clinical trial results point to continued refinement of supportive care for Parkinson’s patients: four weeks of intensive inpatient rehabilitation improved quality of life and motor function over subsequent months. Together, the updates underscore a growing emphasis on practical regimen optimization and functional outcomes beyond symptom scores—areas where clinicians need actionable guidance in day-to-day care decisions.